Correlation between mesenteric fat thickness and serum apolipoproteins in patients with peripheral arterial occlusive disease

Lipids in Health and Disease

Achilleas Chatziioannou²  Despina N Perrea³  Christos Klonaris¹  Dimitrios Gargas²  Ioannis Kornezos²  Ioannis Ioannidis²  Ilias Doulamis³  Panagiotis Konstantopoulos³  Laskarina-Maria Korou³  Irene Tzanetakou³  Ioannis S Vlachos³  Vanessa Safarika²  Apostolos Perelas³ 

[1] Vascular Division, 1st Department of Surgery, Laikon Hospital, University of Athens Medical School, 15b Agiou Thoma Street, Goudi, Athens, 11527, Greece;Department of Interventional Radiology, Aretaieion University Hospital, University of Athens Medical School, 15b Agiou Thoma Street, Goudi, Athens, 11527, Greece;Laboratory for Experimental Surgery and Surgical Research "N.S. Christeas", University of Athens Medical School, 15b Agiou Thoma Street, Goudi, Athens, 11527, Greece

关键词: Atherosclerosis;    Apolipoproteins;    Adipose tissue;    Mesenteric fat thickness;    Ultrasound;   

Others  :  1160193
DOI  :  10.1186/1476-511X-11-125

 received in 2012-07-28, accepted in 2012-09-14,  发布年份 2012

【 摘 要 】

Background

Visceral fat possesses the most detrimental potential for cardiovascular morbidity through the release of adipokines, as well as metabolic and proinflammatory mediators, which adversely affect metabolic and vascular homeostasis. Among the different types of visceral adipose tissue, mesenteric fat is considered particularly detrimental, due to its close proximity to the portal circulation, affecting directly the liver, which is the main regulator of body metabolic homeostasis. Mesenteric fat can be reliably estimated using abdominal ultrasonography, the only available imaging method able to depict individual mesenteric leaves. Aim of the present study was to investigate the correlation of mesenteric fat thickness (MFT) with serum apolipoprotein levels in patients undergoing digital subtraction angiography in a single center.

Methods

35 male patients with peripheral arterial disease were examined. After careful examination of the periumbilical area, the mesenteric leaves were identified. The maximal distance between each pair of sequential leaves was measured, and the mean value of the three thickest leaves was determined as the mesenteric fat thickness. Six apolipoprotein fasting serum concentrations were measured using a Luminex proteomics platform (xMAP Multiplex immunoassay): apolipoprotein A-I (apoAI), apolipoprotein A-II (apoAII), apolipoprotein B (apoB), apolipoprotein C-II (apoCII), apolipoprotein C-III (apoCIII) and apolipoprotein E (apoE).

Results

MFT correlated with apoAII and apoB serum concentrations. The correlations with apoAII and apoB remained significant following correction for BMI. No correlations were noted between MFT and serum apoAI, apoCII, apoCIII or apoE levels before or after adjustment for BMI.

Conclusions

Our study indicates that MFT is significantly correlated with the concentration of atherogenic low density lipoproteins particles, as well as with apoAII, a determinant of free fatty acids levels. No correlation was observed between mesenteric fat thickness and very low density lipoprotein or chylomicron particles concentration.

【 授权许可】

   
2012 Perelas et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Deitel M: The international obesity task force and "globesity". Obes Surg 2002, 12:613-614.
• [2]Kelly T, Yang W, Chen CS, Reynolds K, He J: Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008, 32:1431-1437.
• [3]Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH: The disease burden associated with overweight and obesity. JAMA 1999, 282:1523-1529.
• [4]Ohman MK, Wright AP, Wickenheiser KJ, Luo W, Eitzman DT: Visceral adipose tissue and atherosclerosis. Curr Vasc Pharmacol 2009, 7:169-179.
• [5]Vlachos IS, Hatziioannou A, Perelas A, Perrea DN: Sonographic assessment of regional adiposity. AJR Am J Roentgenol 2007, 189:1545-1553.
• [6]Davidson MH: Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol 2009, 32:482-486.
• [7]Scanu AM, Edelstein C: HDL: bridging past and present with a look at the future. FASEB J 2008, 22:4044-4054.
• [8]Tian L, Xu Y, Fu M, Jia L, Yang Y: Influence of apolipoproteinCII concentrations on HDL subclass distribution. J Atheroscler Thromb 2009, 16:611-620.
• [9]Kawakami A, Yoshida M: Apolipoprotein CIII links dyslipidemia with atherosclerosis. J Atheroscler Thromb 2009, 16:6-11.
• [10]Mahley RW, Ji ZS: Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999, 40:1-16.
• [11]Perrini S, Leonardini A, Laviola L, Giorgino F: Biological specificity of visceral adipose tissue and therapeutic intervention. Arch Physiol Biochem 2008, 114:277-286.
• [12]Ouchi N, Ohashi K, Shibata R, Murohara T: Adipocytokines and obesity-linked disorders. Nagoya J Med Sci 2012, 74:19-30.
• [13]Liu KH, Chan YL, Chan WB, Chan JC, Chu CW: Mesenteric fat thickness is an independent determinant of metabolic syndrome and identifies subjects with increased carotid intima-media thickness. Diabetes Care 2006, 29:379-384.
• [14]Bazzocchi A, Filonzi G, Ponti F, Sassi C, Salizzoni E, Battista G, Canini R: Accuracy, reproducibility and repeatability of ultrasonography in the assessment of abdominal adiposity. Acad Radiol 2011, 18:1133-1143.
• [15]Liu KH, Chan YL, Chan JC, Chan WB: Association of carotid intima-media thickness with mesenteric, preperitoneal and subcutaneous fat thickness. Atherosclerosis 2005, 179:299-304.
• [16]Liu KH, Chan YL, Chan JC, Chan WB, Kong WL: Mesenteric fat thickness as an independent determinant of fatty liver. Int J Obes (Lond) 2006, 30:787-793.
• [17]Liu KH, Chan YL, Chan WB, Kong WL, Kong MO, Chan JC: Sonographic measurement of mesenteric fat thickness is a good correlate with cardiovascular risk factors: comparison with subcutaneous and preperitoneal fat thickness, magnetic resonance imaging and anthropometric indexes. Int J Obes Relat Metab Disord 2003, 27:1267-1273.
• [18]Derchi LE, Solbiati L, Rizzatto G, De Pra L: Normal anatomy and pathologic changes of the small bowel mesentery: US appearance. Radiology 1987, 164:649-652.
• [19]Ma RC, Liu KH, Lam PM, Cheung LP, Tam WH, Ko GT, Chan MH, Ho CS, Lam CW, Chu WC, et al.: Sonographic measurement of mesenteric fat predicts presence of fatty liver among subjects with polycystic ovary syndrome. J Clin Endocrinol Metab 2011, 96:799-807.
• [20]Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343-1351.
• [21]Pelletier-Beaumont E, Arsenault BJ, Almeras N, Bergeron J, Tremblay A, Poirier P, Despres JP: Normalization of visceral adiposity is required to normalize plasma apolipoprotein B levels in response to a healthy eating/physical activity lifestyle modification program in viscerally obese men. Atherosclerosis 2012, 221:577-582.
• [22]Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C: Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990, 10:497-511.
• [23]Ng TW, Chan DC, Barrett PH, Watts GF: Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome. Clin Sci (Lond) 2010, 118:79-85.
• [24]Krauss RM, Siri PW: Metabolic abnormalities: triglyceride and low-density lipoprotein. Endocrinol Metab Clin North Am 2004, 33:405-415.
• [25]Meshkani R, Adeli K: Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009, 42:1331-1346.
• [26]Yu YH, Ginsberg HN: Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res 2005, 96:1042-1052.
• [27]Karagiannides I, Pothoulakis C: Neuropeptides, mesenteric fat, and intestinal inflammation. Ann N Y Acad Sci 2008, 1144:127-135.
• [28]Bartolome N, Rodriguez L, Martinez MJ, Ochoa B, Chico Y: Upregulation of apolipoprotein B secretion, but not lipid, by tumor necrosis factor-alpha in rat hepatocyte cultures in the absence of extracellular fatty acids. Ann N Y Acad Sci 2007, 1096:55-69.
• [29]Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH: Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005, 54:795-802.
• [30]Pittas AG, Joseph NA, Greenberg AS: Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004, 89:447-452.
• [31]Qin B, Anderson RA, Adeli K: Tumor necrosis factor-alpha directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling. Am J Physiol Gastrointest Liver Physiol 2008, 294:G1120-G1129.
• [32]Arai T, Yamashita S, Hirano K, Sakai N, Kotani K, Fujioka S, Nozaki S, Keno Y, Yamane M, Shinohara E, et al.: Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb 1994, 14:1129-1136.
• [33]Kobayashi H, Nakamura T, Miyaoka K, Nishida M, Funahashi T, Yamashita S, Matsuzawa Y: Visceral fat accumulation contributes to insulin resistance, small-sized low-density lipoprotein, and progression of coronary artery disease in middle-aged non-obese Japanese men. Jpn Circ J 2001, 65:193-199.
• [34]Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C: The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis 2005, 183:308-315.